Novel therapeutic strategy to prevent immune escape in metastatic NSCLC through combined PD-1 and Id1 blockade
According to the Global Cancer Observatory (http://gco.iarc.fr), primary lung cancer ranks as the most common tumor worldwide and the leading cause of cancer-related mortality. In 2020, 2.2 million new lung cancer cases were diagnosed, which comprises 12.2% of total cancers.
Main Authors: | Baraibar-Argota, I. (Iosune), Gil-Bazo, I. (Ignacio) |
---|---|
Format: | info:eu-repo/semantics/doctoralThesis |
Language: | eng |
Published: |
Universidad de Navarra
2021
|
Subjects: | |
Online Access: | https://hdl.handle.net/10171/61070 |
Similar Items
-
Prognostic capacity of peripheral blood-derived biomarkers in NSCLC patients treated with PD-1/PD-L1 blockade immunotherapy
by: Fernández-Hinojal, G. (Gonzalo), et al.
Published: (2022) -
Comprehensive Analysis of SWI/SNF Inactivation in Lung Adenocarcinoma Cell Models
by: Peinado, P. (Paola), et al.
Published: (2023) -
Cancer cell-intrinsic alterations associated with an immunosuppressive tumor microenvironment and resistance to immunotherapy in lung cancer
by: Otegui, N. (Nerea), et al.
Published: (2023) -
Automation of early lung cancer detection
by: Pengo, T. (Thomas), et al.
Published: (2011) -
Two cell line models to study multiorganic metastasis and immunotherapy in lung squamous cell carcinoma
by: Valencia, K. (Karmele), et al.
Published: (2023)